We are live on ! Find out more
VVM

Versant Venture Management Portfolio holdings

AUM $141M
1-Year Est. Return 190.82%
This Fund
S&P 500
This Quarter Est. Return
-16.92%
1 Year Est. Return
+190.82%
3 Year Est. Return
+375.7%
5 Year Est. Return
+81.85%
10 Year Est. Return
+4,735.29%
AUM
$65.2M
AUM Growth
-$34.9M
Cap. Flow
-$17.8M
Cap. Flow %
-27.25%
Top 10 Hldgs %
100%
Holding
10
New
–
Increased
–
Reduced
–
Closed
2

Top Buys

No buys this quarter

Top Sells

Rank Stock Value
1
CRNX icon
Crinetics Pharmaceuticals
CRNX
+$9.01M
2
AKRO
Akero Therapeutics
AKRO
+$8.77M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CRSP icon
1
CRISPR Therapeutics
CRSP
$4.68B
$30.3M 46.45%
498,558
– –
PASG icon
2
Passage Bio
PASG
$14.7M
$11.7M 17.94%
247,988
– –
GRTS
3
DELISTED
Gritstone bio, Inc. Common Stock
GRTS
$8.62M 13.21%
3,561,150
– –
ADVM
4
DELISTED
Adverum Biotechnologies
ADVM
$6.08M 9.32%
506,823
– –
UTRS
5
DELISTED
Minerva Surgical, Inc. Common Stock
UTRS
$3.93M 6.03%
83,685
– –
ALGS icon
6
Aligos Therapeutics
ALGS
$26.3M
$2.81M 4.3%
92,815
– –
CBAY
7
DELISTED
Cymabay Therapeutics
CBAY
$1.6M 2.46%
543,753
– –
CLVS
8
DELISTED
Clovis Oncology, Inc.
CLVS
$183K 0.28%
101,855
– –
AKRO
9
DELISTED
Akero Therapeutics
AKRO
– –
-617,727
Closed -$8.77M
CRNX icon
10
Crinetics Pharmaceuticals
CRNX
$8.88B
– –
-410,360
Closed -$9.01M

Similar funds

POIA
Pin Oak Investment Advisors Houston, Texas $141M AUM 20.83% 1-Year Est. Return
MAM
Maytree Asset Management Hong Kong $141M AUM 114% 1-Year Est. Return
TM
TFJ Management Somerville, Massachusetts $141M AUM 9.28% 1-Year Est. Return
IA
IF Advisors San Antonio, Texas $141M AUM
KCM
Kalehua Capital Management Dallas, Texas $141M AUM
RB
Renasant Bank Tupelo, Mississippi $141M AUM 16.9% 1-Year Est. Return
YEPX
Yorktown Energy Partners XI New York $142M AUM 130.51% 1-Year Est. Return
CFGW
Chancellor Financial Group WB Wilkes-Barre, Pennsylvania $141M AUM 23.22% 1-Year Est. Return

Versant Venture Management's Q2 2022 Portfolio in Review

As of Q2 2022, Versant Venture Management held 10 positions worth $65.2M, down 35% from $100M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Versant Venture Management withdrew a net $17.8M in Q2 2022, closing 2 positions. Its most notable exit was Crinetics Pharmaceuticals, an estimated $9.01M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • Versant Venture Management fully exited Crinetics Pharmaceuticals in Q2 2022, selling an estimated $9.01M.
  • Versant Venture Management's ten largest holdings make up 100% of its $65.2M portfolio in Q2 2022.
  • Versant Venture Management opened 0 new positions and closed 2 in Q2 2022.
  • Versant Venture Management's portfolio value fell 35% quarter-over-quarter to $65.2M.

Based on Versant Venture Management's 13F filing for Q2 2022, filed 11 Aug 2022.